

Contents

Preface	5
Chapter 1: Family planning—expanding the choices	9
As the end-users see it	9
- Contraceptive methods—selecting, staying, stopping, switching	10
Safety of existing family planning methods	11
- The safety of implants	11
- The safety of progestin-only contraceptives	12
- The safety of intrauterine devices (IUDs)	14
- The safety of vasectomy	15
Efficacy of existing family planning methods	16
- The effectiveness of the female condom	17
Expanding choice through new or better methods	18
- Emergency contraception	18
- Male hormonal contraceptives	21
- Immunocontraception for women	22
Boxes	
1.1. Endometrial bleeding—back to basics	13
1.2. Team work for implantation research	20
1.3. Intrauterine devices—any time	21
Figures	
1.1. Percentages of women discontinuing use of contraceptive methods within one year of starting	10
1.2. Percentage of men who have undergone vasectomy in New Zealand, by age-group	17
1.3. Countries using levonorgestrel alone for emergency contraception	19
1.4. Effect on pregnancy rates of delay in taking 10 mg or 25 mg of mifepristone after unprotected sexual intercourse (data from a multicentre study in China)	20
1.5. Sperm concentrations in men receiving testosterone undecanoate during a multicentre trial in China	22
1.6. Sperm concentrations in men receiving testosterone undecanoate (TU), either alone or with depot-medroxyprogesterone acetate (DMPA), during a trial in Indonesia	23
Tables	
1.1. The cumulative ten-year probability (as of June 2001), expressed as a percentage, of a woman discontinuing the TCU-380A and Multiload-375 intrauterine devices, by reason for discontinuing	15
1.2. The cumulative six-year probability (as of December 2001), expressed as a percentage, of a woman discontinuing the TCU-380A intrauterine device and the Mirena levonorgestrel-releasing device	16

Chapter 2: Making pregnancy safer	25
Improving maternal health	26
- Preventing eclampsia	26
- Identifying the most effective antenatal care strategy	27
- Reducing postpartum haemorrhage	28
- Reducing unnecessary caesarean sections	28
Measuring maternal mortality and its causes	28
Boxes	
2.1. The best evidence at a click	29
Figures	
2.1. Number of subscriptions, by WHO region, to the WHO Reproductive Health Library during the reporting biennium	29
Tables	
2.1. Causes of maternal and neonatal deaths, and principal interventions required	26
Chapter 3: Preventing reproductive tract infections	31
Mapping the prevalence of reproductive tract infections	32
Preventing reproductive tract infections	33
- Condoms for men	33
- Condoms for women	33
- Microbicides and spermicides	34
Human papillomavirus and cervical cancer	34
Preventing HIV infection	35
Boxes	
3.1. Preventing mother-to-child transmission of HIV—an expert view	35
Tables	
3.1. Estimated annual incidence of curable sexually transmitted infections worldwide for 1999 (the latest year for which reliable data are available)	32
3.2. Estimated annual incidence and incidence rate of curable sexually transmitted infections in the 15–49-year age-group by region and worldwide for 1999 (the latest year for which reliable data are available)	32
3.3. Rate (%) of mother-to-child transmission of HIV in relation to breastfeeding	36
Chapter 4: Preventing unsafe abortion	37
Safe abortion everywhere—without surgery	38
The dynamics and determinants of abortion	38
- Family planning and preference for male babies	38
- Medicine vs surgery	40

- Emergency contraception vs abortion	40
- Legal constraints	41
- Physicians vs non-physicians	41

Boxes

4.1. Smaller is better for medical abortion	39
---	----

Tables

4.1. Preferences between medical and surgical abortion among 400 women with experience of both methods, interviewed in Tianjin, China	40
---	----

Chapter 5: Exploring adolescent reproductive health 43

Risky sexual behaviour	43
-------------------------------	-----------

Adolescents in vulnerable settings	44
---	-----------

Unwanted or non-consensual sexual activity	44
---	-----------

Consequences of risky sexual behaviour	45
---	-----------

Obstacles to seeking care	45
----------------------------------	-----------

Figures

5.1. Percentages of adolescents reporting sexual coercion in a study in Nigeria	45
---	----

Chapter 6: Cooperating with countries 47

Working with regions	47
-----------------------------	-----------

- Africa and the Eastern Mediterranean	49
--	----

- The Americas	51
----------------	----

- Asia and the Pacific	53
------------------------	----

- Eastern and Central Europe	53
------------------------------	----

Working with countries	54
-------------------------------	-----------

Boxes

6.1. Grants for building research capacity	49
--	----

6.2. Workshops debate ethics	51
------------------------------	----

6.3. Female genital mutilation	52
--------------------------------	----

6.4. A patient path from research to public policy	54
--	----

6.5. Countries using the HRP strategic approach	56
---	----

6.6. Women's and men's rights in reproductive health	57
--	----

Figures

6.1. During the 2000–2001 biennium, 123 research centres in 59 countries (shaded in this map) participated in HRP activities and/or received some form of support from HRP. Together they make up HRP's global research network	48
---	----

6.2. Estimated prevalence rates of female genital mutilation in Africa	52
6.3. A “systems framework”, that HRP has borrowed from business management to develop its “strategic approach” to countries wishing to improve the quality of reproductive health care they provide to their populations	55

Tables

6.1. Numbers of HRP grants awarded to institutions during the 2000–2001 biennium, by region and type of grant	50
6.2. Numbers of researchers who received individual HRP research training grants during the 2000–2001 biennium, by sex, research area, and region	50

Annex I: Financial overview for the biennium 2000–2001 59

Sources of income 59

Figures

I.1. Funds received in relation to approved budgets during 1988–2001	59
--	----

Tables

I.1. HRP income, 1970–2001	60
----------------------------	----

Annex II: Centres collaborating with HRP during 2000–2001 61

Annex III: HRP Staff, December 2001 67